Skip to main content

View full-text article in PMC

. 2011 Oct 14;17(38):4289–4297. doi: 10.3748/wjg.v17.i38.4289

Table 2.

Bax expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	73.52 ± 0.83^e ^a	56.43 ± 0.74^e ^a	36.47 ± 1.21^e ^a
rAd-p53	5 × 10⁶	0	63.25 ± 1.32^c ^a	53.86 ± 1.54^c ^a	33.71 ± 1.41^c ^a
	5 × 10⁷	0	76.14 ± 0.73^c ^a	59.32 ± 1.45^c ^a	39.47 ± 1.03^c ^a
	5 × 10⁸	0	79.62 ± 1.46^c ^a	64.74 ± 1.08^c ^a	41.35 ± 1.15^c ^a
	5 × 10⁹	0	82.54 ± 1.28^c ^a	69.53 ± 1.02^c ^a	43.75 ± 1.1^c ^a
rAd-p53 + OXA	5 × 10⁶	3.2	78.82 ± 0.88^e ^c ^a	58.64 ± 1.07^e ^c ^a	49.15 ± 1.04^e ^c ^a
	5 × 10⁷	3.2	84.32 ± 1.02^e ^c ^a	62.74 ± 1.19^e ^c ^a	52.9 ± 1.31^e ^c ^a
	5 × 10⁸	3.2	87.41 ± 1.03^e ^c ^a	67.38 ± 1.14^e ^c ^a	55.23 ± 1.06^e ^c ^a
	5 × 10⁹	3.2	89.71 ± 0.36^e ^c ^a	75.14 ± 1.65^e ^c ^a	58.67 ± 1.12^e ^c ^a
Control	0	0	26.32 ± 1.04	19.91 ± 0.87	16.74 ± 1.23

^a

P < 0.05 vs control;

^c

P < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^e

P < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.